ポンペ病(Pompe Disease):治療薬開発のグローバルパイプライン分析(2014年上半期)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GMDHC5127IDB)
◆英語タイトル:Pompe Disease - Pipeline Review, H1 2014
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC5127IDB
◆発行日:2014年6月15日
◆調査対象地域:グローバル
◆ページ数:63
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[ポンペ病(Pompe Disease):治療薬開発のグローバルパイプライン分析(2014年上半期)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Pompe Disease – Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Pompe Disease – Pipeline Review, H1 2014’, provides an overview of the Pompe Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pompe Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pompe Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pompe Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pompe Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pompe Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pompe Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pompe Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pompe Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Pompe Disease Overview 7
Therapeutics Development 8
Pipeline Products for Pompe Disease – Overview 8
Pipeline Products for Pompe Disease – Comparative Analysis 9
Pompe Disease – Therapeutics under Development by Companies 10
Pompe Disease – Therapeutics under Investigation by Universities/Institutes 12
Pompe Disease – Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Pompe Disease – Products under Development by Companies 16
Pompe Disease – Products under Investigation by Universities/Institutes 17
Pompe Disease – Companies Involved in Therapeutics Development 18
Genzyme Corporation 18
Sangamo BioSciences, Inc. 19
BioMarin Pharmaceutical Inc. 20
Amicus Therapeutics, Inc. 21
EpiVax, Inc. 22
Valerion Therapeutics 23
Oxyrane Belgium NV 24
Pompe Disease – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
BMN-701 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
GZ-402666 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
duvoglustat hydrochloride + alglucosidase alfa – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
rAAV1-CMV-GAA – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ZFP Transcription Factors for Lysosomal Storage Diseases – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
OXY-2810 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Tregitopes for Pompe disease – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ATB-200 + Chaperone – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AT-002 – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
VAL-1221 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Pompe Disease – Recent Pipeline Updates 46
Pompe Disease – Dormant Projects 51
Pompe Disease – Product Development Milestones 52
Featured News & Press Releases 52
May 27, 2014: BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease 52
Mar 19, 2013: BioMarin Announces Results From Phase I/II Trial Of BMN-701 For Treatment Of Pompe Disease, Plans To Initiate Phase II/III Trial 53
Feb 07, 2013: Amicus Therapeutics To Present Data On Its Pharmacological Chaperones At Lysosomal Disease Network WORLD Symposium 54
Jan 04, 2013: Amicus Therapeutics Announces Positive Results From All Four Cohorts In Phase II Chaperone-enzyme Replacement Therapy Co-Administration Study For Pompe Disease 55
Oct 11, 2012: Amicus Therapeutics Announces Positive Pompe Program Updates 57
Jun 26, 2012: Amicus Announces Positive Preliminary Results From Phase II Chaperone-Enzyme Replacement Therapy Co-Administration Study For Pompe Disease 59
Jan 21, 2010: Genzyme Announces Six-Month FDA Review For Lumizyme BLA 60
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 63

List of Tables
Number of Products under Development for Pompe Disease, H1 2014 8
Number of Products under Development for Pompe Disease - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Pompe Disease - Pipeline by Genzyme Corporation., H1 2014 18
Pompe Disease - Pipeline by Sangamo BioSciences, Inc., H1 2014 19
Pompe Disease - Pipeline by BioMarin Pharmaceutical Inc., H1 2014 20
Pompe Disease - Pipeline by Amicus Therapeutics, Inc., H1 2014 21
Pompe Disease - Pipeline by EpiVax, Inc., H1 2014 22
Pompe Disease - Pipeline by Valerion Therapeutics, H1 2014 23
Pompe Disease - Pipeline by Oxyrane Belgium NV, H1 2014 24
Assessment by Monotherapy Products, H1 2014 25
Assessment by Combination Products, H1 2014 26
Number of Products by Stage and Target, H1 2014 28
Number of Products by Stage and Mechanism of Action, H1 2014 30
Number of Products by Stage and Route of Administration, H1 2014 32
Number of Products by Stage and Molecule Type, H1 2014 34
Pompe Disease Therapeutics - Recent Pipeline Updates, H1 2014 46
Pompe Disease - Dormant Projects, H1 2014 51

List of Figures
Number of Products under Development for Pompe Disease, H1 2014 8
Number of Products under Development for Pompe Disease - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 25
Assessment by Combination Products, H1 2014 26
Number of Products by Top 10 Target, H1 2014 27
Number of Products by Stage and Top 10 Target, H1 2014 28
Number of Products by Top 10 Mechanism of Action, H1 2014 29
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 30
Number of Products by Top 10 Route of Administration, H1 2014 31
Number of Products by Stage and Top 10 Route of Administration, H1 2014 32
Number of Products by Top 10 Molecule Type, H1 2014 33
Number of Products by Stage and Top 10 Molecule Type, H1 2014 34

*** 掲載企業 ***

Genzyme Corporation
Sangamo BioSciences, Inc.
BioMarin Pharmaceutical Inc.
Amicus Therapeutics, Inc.
EpiVax, Inc.
Valerion Therapeutics
Oxyrane Belgium NV

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC5127IDB )"ポンペ病(Pompe Disease):治療薬開発のグローバルパイプライン分析(2014年上半期)" (英文:Pompe Disease - Pipeline Review, H1 2014)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。